Market research
MRNA Moderna Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 55B
- P/E ratio
- Not available
- Analyst target
- 95.6667
- Dividend yield
- Not available
- Beta
- 0.9
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US60770K1079
- Market cap
- 55B
- P/E ratio
- Not available
- Analyst target
- 95.6667
- Dividend yield
- Not available
- Beta
- 0.9
About
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MRNA discussion.
5 years, 4 months ago
Moderna, Inc is currently in a long term uptrend where the price is trading 61.3% above its 200 day moving average.
From a valuation standpoint, the stock is 95.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 62.9.
Moderna, Inc's total revenue rose by 3960.8% to $571M since the same quarter in the previous year.
Its net income has dropped by 121.3% to $-272M since the same quarter in the previous year.
Finally, its free cash flow grew by 1311.5% to $1B since the same quarter in the previous year.
Based on the above factors, Moderna, Inc gets an overall score of 4/5.